Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932493 | 1.00 | KDM4E (0.40) | KDM4ENPC1RAB9AFFAR1LMNA | |
| SCHEMBL1932001 | 1.00 | KDM4E (0.40) | KDM4ENPC1RAB9AFFAR1LMNA | |
| SCHEMBL17266821 | 0.87 | KDM4E (0.39) | KDM4ENPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL1932607 | 0.84 | APP (0.40) | FFAR1ALDH1A1PKMUSP2GAA | |
| SCHEMBL1931785 | 0.84 | APP (0.40) | FFAR1ALDH1A1PKMUSP2GAA | |
| SCHEMBL1932297 | 0.84 | APP (0.40) | FFAR1ALDH1A1PKMUSP2GAA | |
| SCHEMBL6902296 | 0.83 | NPC1 (0.37) | KDM4ENPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL1904197 | 0.83 | NPC1 (0.37) | KDM4ENPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL1905236 | 0.83 | NPC1 (0.37) | KDM4ENPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL13471787 | 0.82 | NPC1 (0.36) | KDM4ENPC1RAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852573-B1 | N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-02-01 | — | — | EP | disclosed |
| EP-2852573-B1 | N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9309198-B2 | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9309198-B2 | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| WO-2011051165-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | GUCY1A2, GUCY1A1, GUCY1B2 | KDM4E 2173/4885NPC1 1782/4885RAB9A 2844/4885 |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | KDM4E 3557/4885NPC1 577/4885RAB9A 3852/4885 |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | KDM4E 3557/4885NPC1 577/4885RAB9A 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.